Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 215

1.

Measuring Healthcare-Associated Infection Outcomes: Enhanced Surveillance to Include Process Adherence for Quality Improvement.

Burrell SJ, Bull AL, Worth LJ.

Stud Health Technol Inform. 2019 Aug 21;264:1833-1834. doi: 10.3233/SHTI190671.

PMID:
31438366
2.

Diagnosis, management and prevention of Candida auris in hospitals: position statement of the Australasian Society for Infectious Diseases.

Ong CW, Chen SC, Clark JE, Halliday CL, Kidd SE, Marriott DJ, Marshall CL, Morris AJ, Morrissey CO, Roy R, Slavin MA, Stewardson AJ, Worth LJ, Heath CH; Australian and New Zealand Mycoses Interest Group (ANZMIG); and the Healthcare Infection Control Special Interest Group (HICSIG); both of the Australasian Society for Infectious Diseases (ASID).

Intern Med J. 2019 Oct;49(10):1229-1243. doi: 10.1111/imj.14612.

PMID:
31424595
3.

The current scope of healthcare-associated infection surveillance activities in hospitalized immunocompromised patients: a systematic review.

Valentine JC, Hall L, Verspoor KM, Worth LJ.

Int J Epidemiol. 2019 Jul 30. pii: dyz162. doi: 10.1093/ije/dyz162. [Epub ahead of print]

PMID:
31363780
4.

Auditing fungal disease in leukemia patients in a tertiary care center: opportunities and challenges for an antifungal stewardship program.

Paige E, Haywood P, Xie M, Worth L, Thursky K, Urbancic K, Bajel A, Slavin M.

Leuk Lymphoma. 2019 Oct;60(10):2373-2383. doi: 10.1080/10428194.2019.1590570. Epub 2019 May 17.

PMID:
31096813
5.

FDG-PET/CT in managing infection in patients with hematological malignancy: clinician knowledge and experience in Australia.

Douglas AP, Thursky KA, Worth LJ, Harrison SJ, Hicks RJ, Slavin MA.

Leuk Lymphoma. 2019 Oct;60(10):2471-2476. doi: 10.1080/10428194.2019.1590571. Epub 2019 Apr 5.

PMID:
30947578
6.

Skin and soft tissue infections and current antimicrobial prescribing practices in Australian aged care residents.

Bennett NJ, Imam N, Ingram RJ, James RS, Buising KL, Bull AL, Chen CS, Thursky KA, Worth LJ.

Epidemiol Infect. 2019 Jan;147:e87. doi: 10.1017/S0950268819000128.

7.

Better Sepsis Management Rather Than Fluoroquinolone Prophylaxis for Patients With Cancer-Related Immunosuppression.

Slavin MA, Worth LJ, Seymour JF, Thursky KA.

J Clin Oncol. 2019 May 1;37(13):1139-1140. doi: 10.1200/JCO.18.01474. Epub 2019 Mar 7. No abstract available.

PMID:
30844318
8.

Impact of a hospital-wide sepsis pathway on improved quality of care and clinical outcomes in surgical patients at a comprehensive cancer centre.

Hiong A, Thursky KA, Venn G, Teh BW, Haeusler GM, Crane M, Slavin MA, Worth LJ.

Eur J Cancer Care (Engl). 2019 May;28(3):e13018. doi: 10.1111/ecc.13018. Epub 2019 Feb 13.

PMID:
30761632
9.

Sepsis incidence and mortality are underestimated in Australian intensive care unit administrative data.

Valentine JC, Haeusler G, Worth L, Thursky K.

Med J Aust. 2019 Mar;210(4):188-188.e1. doi: 10.5694/mja2.50017. Epub 2019 Feb 13. No abstract available.

PMID:
30761537
10.

Increased incidence of community-associated Staphylococcus aureus bloodstream infections in Victoria and Western Australia, 2011-2016.

Imam N, Tempone S, Armstrong PK, McCann R, Johnson S, Worth LJ, Richards MJ.

Med J Aust. 2019 Feb;210(2):87-88. doi: 10.5694/mja2.12057. Epub 2018 Dec 21. No abstract available.

PMID:
30712305
11.

High rates of proven invasive fungal disease with the use of ibrutinib monotherapy for relapsed or refractory chronic lymphocytic leukemia.

Teh BW, Chui W, Handunnetti S, Tam C, Worth LJ, Thursky KA, Slavin MA.

Leuk Lymphoma. 2019 Jun;60(6):1572-1575. doi: 10.1080/10428194.2018.1543884. Epub 2019 Jan 11. No abstract available.

PMID:
30632838
12.

Statistical Process Control Charts for Monitoring Staphylococcus aureus Bloodstream Infections in Australian Health Care Facilities.

Imam N, Spelman T, Johnson SA, Worth LJ.

Qual Manag Health Care. 2019 Jan/Mar;28(1):39-44. doi: 10.1097/QMH.0000000000000201.

PMID:
30586121
13.

Impact of participation in a surgical site infection surveillance network: results from a large international cohort study.

Abbas M, de Kraker MEA, Aghayev E, Astagneau P, Aupee M, Behnke M, Bull A, Choi HJ, de Greeff SC, Elgohari S, Gastmeier P, Harrison W, Koek MBG, Lamagni T, Limon E, Løwer HL, Lyytikäinen O, Marimuthu K, Marquess J, McCann R, Prantner I, Presterl E, Pujol M, Reilly J, Roberts C, Segagni Lusignani L, Si D, Szilágyi E, Tanguy J, Tempone S, Troillet N, Worth LJ, Pittet D, Harbarth S.

J Hosp Infect. 2019 Jul;102(3):267-276. doi: 10.1016/j.jhin.2018.12.003. Epub 2018 Dec 7.

PMID:
30529703
14.
15.

Infection prevention quality indicators in aged care: ready for a national approach.

Bennett NJ, Bradford JM, Bull AL, Worth LJ.

Aust Health Rev. 2018 Aug 21. doi: 10.1071/AH18052. [Epub ahead of print]

PMID:
30126530
16.

Carbapenemase-producing Enterobacteriaceae in Australian hospitals: outcome of point-prevalence screening in high-risk wards.

Brett JA, Johnson SA, Cameron DRM, Lane CR, Easton M, van Diemen A, Sutton B, Bull AL, Richards MJ, Worth LJ.

J Hosp Infect. 2019 Feb;101(2):163-166. doi: 10.1016/j.jhin.2018.08.008. Epub 2018 Aug 10.

PMID:
30102948
17.

Implementation of a whole of hospital sepsis clinical pathway in a cancer hospital: impact on sepsis management, outcomes and costs.

Thursky K, Lingaratnam S, Jayarajan J, Haeusler GM, Teh B, Tew M, Venn G, Hiong A, Brown C, Leung V, Worth LJ, Dalziel K, Slavin MA.

BMJ Open Qual. 2018 Jul 6;7(3):e000355. doi: 10.1136/bmjoq-2018-000355. eCollection 2018.

18.

Treatment and secondary prophylaxis with ethanol lock therapy for central line-associated bloodstream infection in paediatric cancer: a randomised, double-blind, controlled trial.

Wolf J, Connell TG, Allison KJ, Tang L, Richardson J, Branum K, Borello E, Rubnitz JE, Gaur AH, Hakim H, Su Y, Federico SM, Mechinaud F, Hayden RT, Monagle P, Worth LJ, Curtis N, Flynn PM.

Lancet Infect Dis. 2018 Aug;18(8):854-863. doi: 10.1016/S1473-3099(18)30224-X. Epub 2018 Jun 5.

PMID:
29884572
19.

FDG PET/CT imaging in detecting and guiding management of invasive fungal infections: a retrospective comparison to conventional CT imaging.

Douglas AP, Thursky KA, Worth LJ, Drummond E, Hogg A, Hicks RJ, Slavin MA.

Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):166-173. doi: 10.1007/s00259-018-4062-8. Epub 2018 Jun 7.

PMID:
29882160
20.

Prevalence of infections and antimicrobial prescribing in Australian aged care facilities: Evaluation of modifiable and nonmodifiable determinants.

Bennett N, Imam N, James R, Chen C, Bull A, Thursky K, Buising K, Worth L.

Am J Infect Control. 2018 Oct;46(10):1148-1153. doi: 10.1016/j.ajic.2018.03.027. Epub 2018 May 18.

PMID:
29779689
21.

Infections in patients with chronic lymphocytic leukaemia: Mitigating risk in the era of targeted therapies.

Teh BW, Tam CS, Handunnetti S, Worth LJ, Slavin MA.

Blood Rev. 2018 Nov;32(6):499-507. doi: 10.1016/j.blre.2018.04.007. Epub 2018 Apr 23. Review.

PMID:
29709246
22.

Factors contributing to declination of annual influenza vaccination by healthcare workers caring for cancer patients: An Australian experience.

Surtees TC, Teh BW, Slavin MA, Worth LJ.

Vaccine. 2018 Mar 27;36(14):1804-1807. doi: 10.1016/j.vaccine.2018.02.098. Epub 2018 Mar 2.

PMID:
29503114
23.

Asthma- and IgE-associated polymorphisms affect expression of TH 17 genes.

Worth L, Michel S, Gaertner VD, Kabesch M, Schieck M.

Allergy. 2018 Jun;73(6):1342-1347. doi: 10.1111/all.13422. Epub 2018 Apr 10. No abstract available.

PMID:
29380867
24.

Central and peripheral line-associated bloodstream infections in Australian neonatal and paediatric intensive care units: findings from a comprehensive Victorian surveillance network, 2008-2016.

Worth LJ, Daley AJ, Spelman T, Bull AL, Brett JA, Richards MJ.

J Hosp Infect. 2018 May;99(1):55-61. doi: 10.1016/j.jhin.2017.11.021. Epub 2017 Dec 6.

PMID:
29222036
25.

Predicting Risk of Infection in Patients with Newly Diagnosed Multiple Myeloma: Utility of Immune Profiling.

Teh BW, Harrison SJ, Allison CC, Slavin MA, Spelman T, Worth LJ, Thursky KA, Ritchie D, Pellegrini M.

Front Immunol. 2017 Oct 5;8:1247. doi: 10.3389/fimmu.2017.01247. eCollection 2017.

26.

Validation of healthcare-associated infection surveillance in smaller Australian hospitals.

Hoskins AJ, Worth LJ, Imam N, Johnson SA, Bull AL, Richards MJ, Bennett NJ.

J Hosp Infect. 2018 May;99(1):85-88. doi: 10.1016/j.jhin.2017.10.006. Epub 2017 Oct 12.

PMID:
29031863
27.

Safety and cost benefit of an ambulatory program for patients with low-risk neutropenic fever at an Australian centre.

Teh BW, Brown C, Joyce T, Worth LJ, Slavin MA, Thursky KA.

Support Care Cancer. 2018 Mar;26(3):997-1003. doi: 10.1007/s00520-017-3921-3. Epub 2017 Oct 10.

PMID:
29018966
28.

Impact of a dedicated post-transplant vaccination service at an Australian cancer centre.

Teh BW, Joyce T, Slavin MA, Thursky KA, Worth LJ.

Bone Marrow Transplant. 2017 Dec;52(12):1681-1683. doi: 10.1038/bmt.2017.195. Epub 2017 Sep 18. No abstract available.

PMID:
28920950
29.

Antibiotic Prescribing Practices for Prevention of Surgical Site Infections in Australia: Increased Uptake of National Guidelines after Surveillance and Reporting and Impact on Infection Rates.

Bull AL, Worth LJ, Spelman T, Richards MJ.

Surg Infect (Larchmt). 2017 Oct;18(7):834-840. doi: 10.1089/sur.2017.119. Epub 2017 Sep 8.

PMID:
28885898
30.

Central line-associated bloodstream infections in Australian ICUs: evaluating modifiable and non-modifiable risks in Victorian healthcare facilities.

Spelman T, Pilcher DV, Cheng AC, Bull AL, Richards MJ, Worth LJ.

Epidemiol Infect. 2017 Oct;145(14):3047-3055. doi: 10.1017/S095026881700187X. Epub 2017 Sep 4.

PMID:
28868995
31.

Influenza vaccination of Australian healthcare workers: strategies to achieve high uptake.

Johnson SA, Wang D, Bennett N, Bull AL, Richards MJ, Worth LJ.

Aust N Z J Public Health. 2017 Oct;41(5):545-546. doi: 10.1111/1753-6405.12684. Epub 2017 Jul 16. No abstract available.

PMID:
28712142
32.

Epidemiology of infections and antimicrobial use in Australian haemodialysis outpatients: findings from a Victorian surveillance network, 2008-2015.

Worth LJ, Spelman T, Holt SG, Brett JA, Bull AL, Richards MJ.

J Hosp Infect. 2017 Sep;97(1):93-98. doi: 10.1016/j.jhin.2017.05.018. Epub 2017 May 30.

PMID:
28576453
33.

Impact of an Integrated Antibiotic Allergy Testing Program on Antimicrobial Stewardship: A Multicenter Evaluation.

Trubiano JA, Thursky KA, Stewardson AJ, Urbancic K, Worth LJ, Jackson C, Stevenson W, Sutherland M, Slavin MA, Grayson ML, Phillips EJ.

Clin Infect Dis. 2017 Jul 1;65(1):166-174. doi: 10.1093/cid/cix244. Review.

34.

Towards precision prevention: Technologies for identifying healthy individuals with high risk of disease.

Nagel ZD, Engelward BP, Brenner DJ, Begley TJ, Sobol RW, Bielas JH, Stambrook PJ, Wei Q, Hu JJ, Terry MB, Dilworth C, McAllister KA, Reinlib L, Worth L, Shaughnessy DT.

Mutat Res. 2017 Aug;800-802:14-28. doi: 10.1016/j.mrfmmm.2017.03.007. Epub 2017 Apr 6. Review.

35.

Influenza vaccination responses: Evaluating impact of repeat vaccination among health care workers.

Leung VKY, Carolan LA, Worth LJ, Harper SA, Peck H, Tilmanis D, Laurie KL, Slavin MA, Sullivan SG.

Vaccine. 2017 May 2;35(19):2558-2568. doi: 10.1016/j.vaccine.2017.03.063. Epub 2017 Apr 3.

PMID:
28385605
36.

Incidence, etiology and timing of infections following azacitidine therapy for myelodysplastic syndromes.

Trubiano JA, Dickinson M, Thursky KA, Spelman T, Seymour JF, Slavin MA, Worth LJ.

Leuk Lymphoma. 2017 Oct;58(10):2379-2386. doi: 10.1080/10428194.2017.1295141. Epub 2017 Feb 28.

PMID:
28278704
37.

Outcomes of children, adolescents, and young adults following allogeneic stem cell transplantation for secondary acute myeloid leukemia and myelodysplastic syndromes-The MD Anderson Cancer Center experience.

Maher OM, Silva JG, Wu J, Liu D, Cooper LJ, Tarek N, Worth L, Lee DA, Petropoulos D, Franklin AR, Zweidler-Mckay P, Wells RJ, Rondon G, Champlin RE, Tewari P.

Pediatr Transplant. 2017 May;21(3). doi: 10.1111/petr.12890. Epub 2017 Feb 3.

PMID:
28160352
38.

Risks factors and outcomes of Clostridium difficile infection in patients with cancer: a matched case-control study.

Hebbard AIT, Slavin MA, Reed C, Trubiano JA, Teh BW, Haeusler GM, Thursky KA, Worth LJ.

Support Care Cancer. 2017 Jun;25(6):1923-1930. doi: 10.1007/s00520-017-3606-y. Epub 2017 Feb 2.

PMID:
28155020
39.

Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients.

Andersson BS, Thall PF, Valdez BC, Milton DR, Al-Atrash G, Chen J, Gulbis A, Chu D, Martinez C, Parmar S, Popat U, Nieto Y, Kebriaei P, Alousi A, de Lima M, Rondon G, Meng QH, Myers A, Kawedia J, Worth LL, Fernandez-Vina M, Madden T, Shpall EJ, Jones RB, Champlin RE.

Bone Marrow Transplant. 2017 Apr;52(4):580-587. doi: 10.1038/bmt.2016.322. Epub 2016 Dec 19.

40.

Return to sender: the need to re-address patient antibiotic allergy labels in Australia and New Zealand.

Trubiano JA, Worth LJ, Urbancic K, Brown TM, Paterson DL; Australasian Society for Infectious Diseases Clinical Research Network, Lucas M; Australasian Society of Clinical Immunology and Allergy, Phillips E.

Intern Med J. 2016 Nov;46(11):1311-1317. doi: 10.1111/imj.13221.

41.

Treatment of Severe Adult Traumatic Brain Injury Using Bone Marrow Mononuclear Cells.

Cox CS Jr, Hetz RA, Liao GP, Aertker BM, Ewing-Cobbs L, Juranek J, Savitz SI, Jackson ML, Romanowska-Pawliczek AM, Triolo F, Dash PK, Pedroza C, Lee DA, Worth L, Aisiku IP, Choi HA, Holcomb JB, Kitagawa RS.

Stem Cells. 2017 Apr;35(4):1065-1079. doi: 10.1002/stem.2538. Epub 2016 Nov 23.

42.

Improving Antimicrobial Stewardship by Antibiotic Allergy Delabeling: Evaluation of Knowledge, Attitude, and Practices Throughout the Emerging Infections Network.

Trubiano JA, Beekmann SE, Worth LJ, Polgreen PM, Thursky KA, Slavin MA, Grayson ML, Phillips EJ.

Open Forum Infect Dis. 2016 Sep 3;3(3):ofw153. eCollection 2016 Sep.

43.

Epidemiology of bloodstream infections in patients with myeloma receiving current era therapy.

Teh BW, Harrison SJ, Slavin MA, Worth LJ.

Eur J Haematol. 2017 Feb;98(2):149-153. doi: 10.1111/ejh.12813. Epub 2016 Oct 10.

PMID:
27717026
44.

Characterising health care-associated bloodstream infections in public hospitals in Queensland, 2008-2012.

Worth LJ, Bull AL, Richards MJ.

Med J Aust. 2016 Sep 19;205(6):282. No abstract available.

PMID:
27627942
45.

The epidemiology of Clostridium difficile infection in patients with cancer.

Hebbard AI, Slavin MA, Reed C, Teh BW, Thursky KA, Trubiano JA, Worth LJ.

Expert Rev Anti Infect Ther. 2016 Nov;14(11):1077-1085. Epub 2016 Sep 21. Review.

PMID:
27606976
46.

Infection risk with immunomodulatory and proteasome inhibitor-based therapies across treatment phases for multiple myeloma: A systematic review and meta-analysis.

Teh BW, Harrison SJ, Worth LJ, Thursky KA, Slavin MA.

Eur J Cancer. 2016 Nov;67:21-37. doi: 10.1016/j.ejca.2016.07.025. Epub 2016 Sep 1. Review.

PMID:
27592069
47.

Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome.

Alatrash G, Thall PF, Valdez BC, Fox PS, Ning J, Garber HR, Janbey S, Worth LL, Popat U, Hosing C, Alousi AM, Kebriaei P, Shpall EJ, Jones RB, de Lima M, Rondon G, Chen J, Champlin RE, Andersson BS.

Biol Blood Marrow Transplant. 2016 Oct;22(10):1792-1800. doi: 10.1016/j.bbmt.2016.06.023. Epub 2016 Jul 1.

48.

Reducing Staphylococcus aureus bloodstream infections associated with peripheral intravenous cannulae: successful implementation of a care bundle at a large Australian health service.

Rhodes D, Cheng AC, McLellan S, Guerra P, Karanfilovska D, Aitchison S, Watson K, Bass P, Worth LJ.

J Hosp Infect. 2016 Sep;94(1):86-91. doi: 10.1016/j.jhin.2016.05.020. Epub 2016 Jun 7.

PMID:
27346623
49.

Epidemiology of Clostridium difficile infections in Australia: enhanced surveillance to evaluate time trends and severity of illness in Victoria, 2010-2014.

Worth LJ, Spelman T, Bull AL, Brett JA, Richards MJ.

J Hosp Infect. 2016 Jul;93(3):280-5. doi: 10.1016/j.jhin.2016.03.014. Epub 2016 Mar 31.

PMID:
27107622
50.

Oral pristinamycin for the treatment of resistant Gram-positive infections in patients with cancer: Evaluation of clinical outcomes.

Teng JC, Lingaratnam SM, Trubiano JA, Thursky KA, Slavin MA, Worth LJ.

Int J Antimicrob Agents. 2016 May;47(5):391-6. doi: 10.1016/j.ijantimicag.2016.01.017. Epub 2016 Mar 12.

PMID:
27089829

Supplemental Content

Support Center